Metabolic and neurological complications of second-generation antipsychotic use in children: A systematic review and meta-analysis of randomized controlled trials

Drug Safety

Volumn 34, Issue 8, 2011, Pages 651-668

  Pringsheim, Tamara ^a   Lam, Darren ^a   Ching, Heidi ^b   Patten, Scott ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Adolescents; Antipsychotics; Aripiprazole; Children; Clozapine; Meta analysis; Metabolic disorders; Neurological disorders; Olanzapine; Paliperidone; Quetiapine; Risperidone; Weight gain; Ziprasidone

Indexed keywords

ALANINE AMINOTRANSFERASE; ARIPIPRAZOLE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CLOZAPINE; HALOPERIDOL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; VALPROATE SEMISODIUM; ZIPRASIDONE;

AKATHISIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIPOLAR DISORDER; BIPOLAR I DISORDER; BLOOD PRESSURE; BODY MASS; CHILD; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; EMBASE; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; LABORATORY TEST; MEDLINE; MENTAL DISEASE; META ANALYSIS; METABOLIC DISORDER; NEUROLOGICAL COMPLICATION; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; MENTAL DISORDERS; METABOLIC DISEASES; NERVOUS SYSTEM DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 79960369701     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11592020-000000000-00000     Document Type: Review

References (50)

1. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51-68 (Pubitemid 29023554)
2. Janno S, Holi M, Tuisku K, et al. Prevalence of neuroleptic induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry 2004; 161: 160-3 (Pubitemid 38419323)
3. DelBello M, Schwiers M, Rosenberg L, et al. A doubleblind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002; 41 (10): 1216-23 (Pubitemid 38338041)
4. Findling R, Robb A, Nyilas M, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008; 11 (165): 1369-72
5. Kryzhanovskaya L, Schulz S, McDougle C, et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009; 48 (1): 60-70
6. Kumra S, Frazier J, Jacobsen L, et al. Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996; 53 (12): 1090-7 (Pubitemid 26422059)
7. Marcus R, Owen R, Kamen L, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009; 48 (11): 1110-9
8. Sallee F, Kurlan R, Goetz C, et al. Ziprasidone treatment of children and adolescents with tourettes syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000; 39 (3): 292-9 (Pubitemid 30127607)
9. Haas M, Unis A, Armenteros J, et al. A6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 2009; 19 (6): 611-21
10. Patel N, Sanchez R, Johnsrud M, et al. Trends in antipsychotic use in Texas Medicaid population of children and adolescents: 1996 to 2000. J Child Adolesc Psychopharmacol 2002; 12 (3): 221-9 (Pubitemid 35191348)
11. Olfson M, Blanco C, Liu L, et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006; 63: 679-85 (Pubitemid 43848299)
12. Newcomer J. Second generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 Suppl. 1: 1-93 (Pubitemid 40677047)
13. Correll C, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second generation antipsychotic medications during first time use in children and adolescents. JAMA 2009; 302 (16): 1765-73
14. Miller D, Caroff S, Davis S, et al. Extrapyramidal side effects of antipsychotics in a randomized trial. Br J Psychiatry 2008; 193 (4): 279-88
15. Woods SW, Martin A, Spector SG, et al. Effects of development on olanzapine-associated adverse events. J Am Acad Child and Adolesc Psychiatry 2002 Dec; 41 (12): 1439-46 (Pubitemid 44698520)
16. Harris RP, Helfand MH, Woolf SH, et al. Current methods of the U.S. Preventive Services Task Force. Am J Prev Med 2001; 20 (3 Suppl.): 22-35
17. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327 (7414): 557-60 (Pubitemid 37088507)
18. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Risperidone in children with autism and serious behavioural problems. N Engl JMed 2002; 347 (5): 314-21
19. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114 (5): e634-41 (Pubitemid 41647671)
20. Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behaviour disorders in children with subaverage IQs. The Risperidone Conduct Study Group. J Am Acad Child Adolesc Psychiatry 2002; 41 (9): 1026-36 (Pubitemid 38338050)
21. Aman M, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Risperidone Disruptive Behavior Study Group. Am J Psychiatry 2002; 159 (8): 1337-46 (Pubitemid 34832715)
22. Van Bellinghen M, De TrochC.Risperidone in the treatment of behavioural disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebocontrolled pilot trial. J Child Adolesc Psychopharmacol 2001; 11 (1): 5-13 (Pubitemid 32295178)
23. Findling R, McNamara N, Branicky L, et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 2000; 39 (4): 509-16 (Pubitemid 30185547)
24. Buitelaar J, van der Gaag R, Cohen-Kettenis P, et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 2001; 62 (4): 239-48 (Pubitemid 32428762)
25. Armenteros J, Lewis J, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/ hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry 2007; 26 (5): 558-65 (Pubitemid 46642572)
26. Haas M, DelBello N, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebocontrolled study. Bipolar Disord 2009; 11 (7): 687-700
27. Reyes M, Buitelaar J, Toren P, et al. A randomized, doubleblind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behaviour disorders. Am J Psychiatry 2006; 163 (3): 402-10 (Pubitemid 44469381)
28. Sikich L, Hamer R, Bashford R, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004; 29 (1): 133-45 (Pubitemid 38068023)
29. Sikich L, Frazier J,McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum disorders (TEOSS) study. Am J Psychiatry 2008; 165 (11): 1420-31
30. Haas M, EerdekensM, Kushner S, et al. Efficacy, safety and tolerability of two risperidone dosing regiments in adolescent schizophrenia: double-blind study. Br J Psychiatry 2009; 194 (2): 158-64
31. Gilbert D, Batterson J, Sethuraman G, et al. Tic reduction with risperidone versus pimozide in a randomized, doubleblind, crossover trial. J Am Acad Child Adolesc Psychiatry 2004; 43 (2): 206-14
32. Gaffney G, Perry P, Lund B, et al. Risperidone versus clonidine in the treatment of children and adolescents with tourettes syndrome. J Am Acad Child Adolesc Psychiatry 2002; 41 (3): 330-6 (Pubitemid 38338155)
33. Nagaraj R, Singhi P, Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 2006; 21 (6): 450-5 (Pubitemid 44069792)
34. Luby J, Mrakotsky C, Stalets M, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 2006; 16 (5): 575-87 (Pubitemid 44737212)
35. Miral S, Gencer O, Inal-Emiroglu F, et al. Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry 2008; 17 (1): 1-8
36. Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007; 164 (10): 1547-56 (Pubitemid 350069734)
37. Hollander E, Wasserman S, Swanson E, et al. A doubleblind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive development disorder. J Child Adolesc Psychopharmacol 2006; 16 (5): 541-8 (Pubitemid 44737209)
38. DelBello M, Chang K,Welge J, et al. A double-blind, placebocontrolled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 2009; 11 (5): 483-93
39. Connor D, McLaughlin T, Jeffers-Terry M. Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. J Child Adolesc Psychopharmacol 2008; 18 (2): 140-56 (Pubitemid 351591434)
40. DelBello M, Kowatch R, Adler C, et al. A double blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006; 45 (3): 305-13
41. Owen R, Sikich L, Marcus R, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009; 124 (6): 1533-40
42. Findling R, Nyilas M, Forbes R, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2009; 70 (10): 1441-51
43. Tramontina S, Zeni C, Ketzer C, et al. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry 2009; 70 (5): 756-64
44. Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 2006; 63 (7): 721-30
45. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and high-dose olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry 2008; 63 (5): 524-9 (Pubitemid 351220784)
46. Mattson N, Ronnemaa T, Juonala M, et al. Childhood predictors of the metabolic syndrome in adulthood: the cardiovascular risk in young finns study. Ann Med 2008; 40: 542-52
47. Al Mamun A, Cramb S, OCallaghan M, et al. Childhood overweight status predicts diabetes at age 21 years: a follow- up study. Obesity (Silver Spring) 2009; 17 (6): 1255-61
48. Juonala M, Jarvisalo M, Maki-Torkko N, et al. Risk factors identified in childhood and decreased carotid artery elasticity in adulthood. Circulation 2005; 112: 1486-93
49. Pulkki-Raback L, Elovainio M, Kivimaki M, et al. Depressive symptoms and the metabolic syndrome in childhood and adulthood: a prospective cohort study. Health Psychol 2009; 28 (1): 108-16
50. Morato E, Druss B, Hartung D, et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second generation antipsychotic drugs. Arch Gen Psychiatry 2010; 67 (1): 17-24